In silico drug discovery made easy
We use Big Data and Artificial Intelligence to
accelerate your novel Drug Development through:
Our very easy to use SaaS platform provides a versatile set of applications to facilitate target identification and elucidate the mechanisms of action (MoA).
From in silico Drug Design to computational prediction of ADME and pharmacokinetics.
Elucidate the Mode of Action (MoA) of specific molecules and rationalize their off-target effects.
In silico screening of libraries, hit & lead expansion and drug repurposing.
Identify and characterize binding sites using Artificial Intelligence approaches.
We are happy to announce that Mind the Byte has recently moved to the Eixample district, which is a more central location for employees and customers. In the heart of Barcelona, the new office is within walking distance of many iconic places such as Casa...
Metformin, the first drug chosen to be tested in a clinical trial aimed to target the biology of aging per se, has been clinically exploited for decades in the absence of a complete understanding of its therapeutic targets or chemical determinants. Now,...
A study published in Nature Medicine by a team led by researchers at the Spanish National Cancer Research Centre (CNIO), with the participation of Mind the Byte, shows that the administration of silibinin in patients with brain metastasis reduces lesions...